NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

表紙
市場調查報告書

中樞神經系統治療藥的市場趨勢·市場佔有率·市場規模的預測 (2021-2028年):疾病·各地區

Central Nervous System Therapeutic Market Size, Share & Trends Analysis Report By Disease (Neurovascular Diseases, CNS Trauma, Mental Health, Neurodegenerative Diseases, Infectious Diseases), By Region, And Segment Forecasts, 2021 - 2028

出版商 Grand View Research, Inc. 商品編碼 989704
出版日期 內容資訊 英文 120 Pages
商品交期: 2-10個工作天內
價格
中樞神經系統治療藥的市場趨勢·市場佔有率·市場規模的預測 (2021-2028年):疾病·各地區 Central Nervous System Therapeutic Market Size, Share & Trends Analysis Report By Disease (Neurovascular Diseases, CNS Trauma, Mental Health, Neurodegenerative Diseases, Infectious Diseases), By Region, And Segment Forecasts, 2021 - 2028
出版日期: 2021年02月08日內容資訊: 英文 120 Pages
簡介

全球中樞神經系統治療藥的市場規模在預測期間內預計將以7.4%的年複合成長率推移,到2028年前將成長到2050億美元的規模。未滿足需求的存在和減輕疾病負擔的政府配合措施等要素將推動該市場的成長。

本報告提供全球中樞神經系統治療藥的市場調查,彙整市場定義和概要,市場成長的各種影響因素分析,疫情趨勢,開發平台(管線)分析,市場規模的轉變·預測,疾病·地區/主要國家等各種區分的明細,競爭環境,主要企業簡介等資訊。

第1章 調查手法·調查範圍

第2章 摘要整理

第3章 市場可變因素·趨勢·展望

  • 市場分類
  • 普及·成長預測製圖
  • 法律規範
  • 開發平台分析
  • 流行病學研究

第4章 產業預測

  • 市場成長的促進因素分析
  • 市場成長的阻礙要素分析

第5章 商業環境分析

  • SWOT分析
  • 波特的五力分析

第6章 競爭分析

  • 主要交易·策略性聯盟
  • 主要企業·近幾年的發展·影響分析
  • 公開企業
  • 非公開企業

第7章 市場預測·趨勢分析:各疾病

  • 神經血管疾病
  • 心理健康
    • 焦慮症
    • 心理障礙
    • 癲癇
    • 精神病性障礙
    • 其他
  • 退化性疾病
    • 阿茲海默症
    • 帕金森氏症
    • 多發性硬化症
    • 亨丁頓舞蹈症
    • 肌肉萎縮性側索硬化症
    • 其他
  • CNS外傷
  • 感染疾病
  • CNS癌症
  • 其他

第8章 市場預測·趨勢分析:各地區·主要國家

  • 北美
    • 美國
    • 加拿大
  • 歐洲
    • 德國
    • 英國
    • 西班牙
    • 法國
    • 義大利
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 韓國
    • 澳洲
  • 南美
    • 巴西
    • 墨西哥
    • 阿根廷
  • 中東·非洲
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國

第9章 企業簡介

目錄
Product Code: GVR-1-68038-516-8

Central Nervous System Therapeutic Market Growth & Trends

The global central nervous system therapeutic market size is expected to reach USD 205.0 billion by 2028, according to a new report by Grand View Research, Inc. The market is expected to expand at a CAGR of 7.4% from 2021 to 2028. High unmet medical needs and government initiatives to reduce the disease burden are driving the market for central nervous system (CNS) therapeutic over the forecast period. According to WHO, the global economy loses due to depression and anxiety is more than USD 1 trillion per year and rising patient base of mental health globally is expected to increase the economy loses by USD 16 trillion in 2030.

The market holds strong future growth opportunities and major players are adopting different marketing strategies such as new product development, collaborations, geographic expansion, mergers and acquisitions, and new product approval, to strengthen their positions. In February 2020, Biogen announced the investment in Sangamo's zinc finger platform to develop therapies for Alzheimer's disease and other neurological diseases. Similarly, the company has an agreement with Ionis Pharmaceutical for the development of drug candidates applicable across a wide range of neurological diseases.

Presence of strong pipeline products by major pharmaceutical companies such as Biogen, H. Lundbeck A/S, Eli Lilly and Company, and others are expected to accelerate market growth over the forecast period. Besides, other pharmaceutical companies are also actively involved in the development of novel therapies and investing heavily to develop effective therapeutics for the treatment of CNS associated diseases.

Most of the late phase development drugs are for the treatment of neurodegenerative disorders such as Alzheimer's disease, multiple sclerosis, Parkinson's disease, and amyotrophic lateral sclerosis. The drug candidates such as aducanumab, brexpiprozole, evobrutinib, solanezumab are some of the potential drugs that could be commercialized in the next five to eight years for the treatment of various indication of neurodegenerative disorders. Apart from neurodegenerative diseases, migraine, schizophrenia, and epilepsy are the major CNS disease indications that have potential drug candidates in pipeline.

The cancer segment is expected to witness the fastest growth rate over the forecast period. Increasing prevalence, high mortality rate, and rising demand for effective treatment are expected to fuel the growth of the market for CNS therapeutic. According to National Cancer Institute estimates, the number of new cases of CNS cancers was 23,890 whereas the number of deaths was 18,020 in the U.S. in 2020.

Pharmaceutical companies are adopting strategies such as product development, merger and acquisition, and collaboration to strengthen their position in market. For instance, Biogen has signed agreements with Ionis Pharmaceuticals, Atalanta Therapeutics, and Sangamo Therapeutics to develop novel therapeutics for the treatment of different disease indications of the central nervous system. Similarly, in January 2020, the CNS Pharmaceuticals has entered into a licensing agreement with MD Anderson Cancer Center to investigate WP1244, a designed DNA-binding agent to cross the blood-brain barriers for the potential treatment of brain cancers.

Central Nervous System Therapeutic Market Report Highlights

  • The neurodegenerative diseases segment accounted for the largest revenue share of nearly 40.0% in 2020 and is anticipated to maintain its dominance over the forecast period
  • Pipeline candidates such as aducanumab, brexpiprozole, evobrutinib, solanezumab are anticipated to drive the neurodegenerative disorder segment from 2021 to 2028
  • The CNS cancer segment is expected to witness the fastest growth rate over the forecast period. Increasing demand for effective treatment is expected to drive the segment
  • In Asia Pacific, the market is estimated to witness the fastest growth over the coming years owing to the increase in treatment rate and betterment of healthcare infrastructure in the region
  • North America held a majority of share in 2020 due to high awareness level in the region and better reimbursement scenario

Table of Contents

Chapter 1 Methodology and Scope

  • 1.1 Research Methodology
  • 1.2 Research Assumptions
    • 1.2.1 Estimates and Forecast Timeline
  • 1.3 Research Methodology
  • 1.4 Information Procurement
    • 1.4.1 Purchased Database
    • 1.4.2 GVR's Internal Database
    • 1.4.3 Secondary Sources
    • 1.4.4 Primary Research
    • 1.4.5 Details of Primary Research
  • 1.5 Information or Data Analysis
    • 1.5.1 Data Analysis Models
  • 1.6 Market Formulation & Validation
  • 1.7 Model Details
    • 1.7.1 Commodity Flow Analysis
      • 1.7.1.1 Approach 1: Commodity flow approach
      • 1.7.1.2 Approach 2: Country wise market estimation using bottom up approach
  • 1.8 Global Market: CAGR Calculation
  • 1.9 List of Secondary Sources
  • 1.10 List of Primary Sources
  • 1.11 Objectives
    • 1.11.1 Objective 1:
    • 1.11.2 Objective 2:
  • 1.12 List of Tables

Chapter 2 Executive Summary

  • 2.1 Market Summary

Chapter 3 Central Nervous System Therapeutics Market Variables, Trends & Scope

  • 3.1 Market Segmentation
  • 3.2 Penetration and Growth Prospect Mapping
  • 3.4 Regulatory Framework
  • 3.5 Pipeline Analysis
  • 3.6 Epidemiology Study

Chapter 4 Central Nervous System Therapeutics Market - Industry Outlook

  • 4.1 Market Driver Analysis
    • 4.1.1 Increasing Prevalence of CNS Disorders
    • 4.1.2 Presence of Strong Pipeline Drugs
    • 4.1.3 Introduction of a Novel Drug Delivery Systems in CNS
  • 4.2 Market Restraint Analysis
    • 4.2.1 High Treatment Cost
    • 4.2.2 Lack of Neurologists and Neurosurgeons

Chapter 5 Business Environment Analysis

  • 5.1 SWOT Analysis; By Factor (Political & Legal, Economic and Technological)
  • 5.2 Porter's Five Forces Analysis

Chapter 6 Competitive Analysis

  • 6.1 Major Deals & Strategic Alliances
  • 6.2 Recent Developments & Impact Analysis, by Key Market Participants
    • 6.2.1 Company/Competition Categorization (Key Innovators, Market Leaders, Expansion)
    • 6.2.3 Innovators
    • 6.2.4 List of Key Distributors and Channel Partners
    • 6.2.5 Key Company Market Share Analysis, 2020
  • 6.3 Public Companies
    • 6.3.1 Company Market Position Analysis
    • 6.3.2 Competitive Dashboard Analysis
  • 6.4 Private Companies
    • 6.4.1 List of Key Emerging Companies /Technology Disruptors/Innovators
    • 6.4.2 Regional Network Map

Chapter 7 Central Nervous System Therapeutics Market - Segment Analysis, By Disease, 2017 - 2028 (USD Million)

  • 7.1 Central Nervous System Therapeutics Market, Disease Outlook Key Takeaways
  • 7.2 Central Nervous System Therapeutics Market: Disease Movement Analysis
  • 7.3 Neurovascular Diseases
    • 7.3.1 Neurovascular Disease Treatment Market, 2017 - 2028 (USD Million)
  • 7.4 Mental Health
    • 7.4.1 Mental Health Treatment Market, 2017 - 2028 (USD Million)
    • 7.4.2 Anxiety Disorders
      • 7.4.2.1 Anxiety Disorders Treatment Market, 2017 - 2028 (USD Million)
    • 7.4.3 Mood disorders
      • 7.4.3.1 Mood Disorder Treatment Market, 2017 - 2028 (USD Million)
    • 7.4.4 Epilepsy
      • 7.4.4.1 Epilepsy Treatment Market, 2017 - 2028 (USD Million)
    • 7.4.5 Psychotic Disorders
      • 7.4.5.1 Psychotic Disorders Treatment Market, 2017 - 2028 (USD Million)
    • 7.4.6 Others
      • 7.4.6.1 Others Market, 2017 - 2028 (USD Million)
  • 7.5 Degenerative Disorders
    • 7.5.1 Degenerative Disorders Treatment Market, 2017 - 2028 (USD million)
    • 7.5.2 Alzheimer's Disease
      • 7.5.2.1 Alzheimer's Disease Treatment Market, 2017 - 2028 (USD Million)
    • 7.5.3 Parkinson's Disease
      • 7.5.3.1 Parkinson's Disease Treatment Market, 2017 - 2028 (USD Million)
    • 7.5.4 Multiple Sclerosis
      • 7.5.4.1 Multiple Sclerosis Treatment Market, 2017 - 2028 (USD Million)
    • 7.5.5 Huntington's Disease
      • 7.5.5.1 Huntington's Disease Treatment Market, 2017 - 2028 (USD Million)
    • 7.5.6 Amyotrophic Lateral Sclerosis
      • 7.5.6.1 Amyotrophic Lateral Sclerosis Treatment Market, 2017 - 2028 (USD Million)
    • 7.5.7 Others
      • 7.5.7.1 Others Treatment Market, 2017 - 2028 (USD Million)
  • 7.6 CNS Trauma
    • 7.6.1 CNS Trauma Treatment Market, 2017 - 2028 (USD Million)
  • 7.7 Infectious Diseases
    • 7.7.1 Infectious Diseases Treatment Market, 2017 - 2028 (USD Million)
  • 7.8 CNS Cancer
    • 7.8.1 Cancer Treatment Market, 2017 - 2028 (USD Million)
  • 7.9 Others
    • 7.9.1 Others Treatment Market, 2017 - 2028 (USD Million)

Chapter 8 Central Nervous System Therapeutics Market- Segment Analysis, By Region, 2017 - 2028 (USD Million)

  • 8.1 Central Nervous System Therapeutics Market: Regional Movement Analysis
  • 8.2 North America
    • 8.2.1 North America, SWOT Analysis
    • 8.2.2 North America Market Estimates and Forecast, 2017 - 2028 (USD Million)
    • 8.2.3 U.S.
      • 8.2.3.1 U.S. Market Estimates and Forecast, 2017 - 2028 (USD Million)
    • 8.2.4 Canada
      • 8.2.4.1 Canada Market Estimates and Forecast, 2017 - 2028 (USD Million)
  • 8.3 Europe
    • 8.3.1 Europe, SWOT Analysis
    • 8.3.2 Europe Market Estimates and Forecast, 2017 - 2028 (USD Million)
    • 8.3.3 Germany
      • 8.3.3.1 Germany Market Estimates and Forecast, 2017 - 2028 (USD Million)
    • 8.3.4 U.K.
      • 8.3.4.1 U.K. Market Estimates and Forecast, 2017 - 2028 (USD Million)
    • 8.3.5 Spain
      • 8.3.5.1 Spain Market Estimates and Forecast, 2017 - 2028 (USD Million)
    • 8.3.6 France
      • 8.3.6.1 France Market Estimates and Forecast, 2017 - 2028 (USD Million)
    • 8.3.7 Italy
      • 8.3.7.1 Italy Market Estimates and Forecast, 2017 - 2028 (USD Million)
  • 8.4 Asia Pacific
    • 8.4.1 Asia Pacific, SWOT Analysis
    • 8.4.2 Asia Pacific Market Estimates and Forecast, 2017 - 2028 (USD Million)
    • 8.4.3 Japan
      • 8.4.3.1 Japan Market Estimates and Forecast, 2017 - 2028 (USD Million)
    • 8.4.4 China
      • 8.4.4.1 China Market Estimates and Forecast, 2017 - 2028 (USD Million)
    • 8.4.5 India
      • 8.4.5.1 India Market Estimates and Forecast, 2017 - 2028 (USD Million)
    • 8.4.6 South Korea
      • 8.4.6.1 South Korea Market Estimates and Forecast, 2017 - 2028 (USD Million)
    • 8.4.8 Australia
      • 8.4.8.1 Australia Market Estimates and Forecast, 2017 - 2028 (USD Million)
  • 8.5 Latin America
    • 8.5.1 Latin America, SWOT Analysis
    • 8.5.2 Latin America Market Estimates and Forecast, 2017 - 2028 (USD Million)
    • 8.5.3 Brazil
      • 8.5.3.1 Brazil Market Estimates and Forecast, 2017 - 2028 (USD Million)
    • 8.5.4 Mexico
      • 8.5.4.1 Mexico Market Estimates and Forecast, 2017 - 2028 (USD Million)
    • 8.5.5 Argentina
      • 8.5.5.1 Argentina Market Estimates and Forecast, 2017 - 2028 (USD Million)
  • 8.6 Middle East & Africa
    • 8.6.1 Middle East & Africa, SWOT Analysis
    • 8.6.2 Middle-East & Africa Market Estimates and Forecast, 2017 - 2028 (USD Million)
    • 8.6.3 South Africa
      • 8.6.3.1 South Africa Market Estimates and Forecast, 2017 - 2028 (USD Million)
    • 8.6.4 Saudi Arabia
      • 8.6.4.1 Saudi Arabia Market Estimates and Forecast, 2017 - 2028 (USD Million)
    • 8.6.5 UAE
      • 8.6.5.1 UAE Market Estimates and Forecast, 2017 - 2028 (USD Million)

Chapter 9 Company Profile

  • 9.1 Company Profiles
    • 9.1.1 Biogen
      • 9.1.1.1 Company overview
      • 9.1.1.2 Financial performance
      • 9.1.1.3 Product benchmarking
      • 9.1.1.4 Strategic initiatives
    • 9.1.2 Otsuka Pharmaceutical Co., Ltd.
      • 9.1.2.1 Company overview
      • 9.1.2.2 Financial performance
      • 9.1.2.3 Product benchmarking
      • 9.1.2.4 Strategic initiatives
    • 9.1.3 Eli Lilly and Company
      • 9.1.3.1 Company overview
      • 9.1.3.2 Financial performance
      • 9.1.3.3 Product benchmarking
      • 9.1.3.4 Strategic initiatives
    • 9.1.4 Merck & Co.
      • 9.1.4.1 Company overview
      • 9.1.4.2 Financial performance
      • 9.1.4.3 Product benchmarking
      • 9.1.4.4 Strategic initiatives
    • 9.1.5 Astra Zeneca
      • 9.1.5.1 Company overview
      • 9.1.5.2 Financial performance
      • 9.1.5.3 Product benchmarking
      • 9.1.5.4 Strategic initiatives
    • 9.1.6 Shire PLC
      • 9.1.6.1 Company overview
      • 9.1.6.2 Financial performance
      • 9.1.6.3 Product benchmarking
      • 9.1.6.4 Strategic initiatives
    • 9.1.7 Novartis AG
      • 9.1.7.1 Company overview
      • 9.1.7.2 Financial performance
      • 9.1.7.3 Product benchmarking
      • 9.1.7.4 Strategic initiatives
    • 9.1.8 Teva Pharmaceutical Industries Ltd.
      • 9.1.8.1 Company overview
      • 9.1.8.2 Financial performance
      • 9.1.8.3 Product benchmarking
      • 9.1.8.4 Strategic initiatives
    • 9.1.9 Johnson & Johnson Services, Inc.
      • 9.1.9.1 Company overview
      • 9.1.9.2 Financial performance
      • 9.1.9.3 Product benchmarking
      • 9.1.9.4 Strategic initiatives
    • 9.1.11 Pfizer, Inc.
      • 9.1.11.1 Company overview
      • 9.1.11.2 Financial performance
      • 9.1.11.3 Product benchmarking
      • 9.1.11.4 Strategic initiatives

List of Tables

  • Table 1 List of Secondary Sources
  • Table 2 Pipeline Analysis
  • Table 3 Epidemiology
  • Table 4 North America CNS Therapeutics Market, By Country, 2017 - 2028 (USD Million)
  • Table 5 North America CNS Therapeutics Market, By Disease, 2017 - 2028 (USD Million)
  • Table 6 U.S. CNS Therapeutics Market, By Disease, 2017 - 2028 (USD Million)
  • Table 7 Canada CNS Therapeutics Market, By Disease, 2017 - 2028 (USD Million)
  • Table 8 Europe CNS Therapeutics Market, By Country, 2017 - 2028 (USD Million)
  • Table 9 Europe CNS Therapeutics Market, By Disease, 2017 - 2028 (USD Million)
  • Table 10 U.K. CNS Therapeutics Market, By Disease, 2017 - 2028 (USD Million)
  • Table 11 France CNS Therapeutics Market, By Disease, 2017 - 2028 (USD Million)
  • Table 12 Spain CNS Therapeutics Market, By Disease, 2017 - 2028 (USD Million)
  • Table 13 Italy CNS Therapeutics Market, By Disease, 2017 - 2028 (USD Million)
  • Table 14 Germany CNS Therapeutics Market, By Disease, 2017 - 2028 (USD Million)
  • Table 15 Asia Pacific CNS Therapeutics Market, By Country, 2017 - 2028 (USD Million)
  • Table 16 Asia Pacific CNS Therapeutics Market, By Disease, 2017 - 2028 (USD Million)
  • Table 17 Japan CNS Therapeutics Market, By Disease 2017 - 2028 (USD Million)
  • Table 18 China CNS Therapeutics Market, By Disease, 2017 - 2028 (USD Million)
  • Table 19 India CNS Therapeutics Market, By Disease, 2017 - 2028 (USD Million)
  • Table 20 Australia CNS Therapeutics Market, By Disease, 2017 - 2028 (USD Million)
  • Table 21 South Korea CNS Therapeutics Market, By Disease, 2017 - 2028 (USD Million)
  • Table 22 Latin America CNS Therapeutics Market, By Country, 2017 - 2028 (USD Million)
  • Table 23 Latin America CNS Therapeutics Market, By Disease, 2017 - 2028 (USD Million)
  • Table 24 Brazil CNS Therapeutics Market, By Disease 2017 - 2028 (USD Million)
  • Table 25 Mexico CNS Therapeutics Market, By Disease, 2017 - 2028 (USD Million)
  • Table 26 Argentina CNS Therapeutics Market, By Disease, 2017 - 2028 (USD Million)
  • Table 27 Middle East & Africa CNS Therapeutics Market, By Country, 2017 - 2028 (USD Million)
  • Table 28 Middle East & Africa CNS Therapeutics Market, By Disease, 2017 - 2028 (USD Million)
  • Table 29 South Africa CNS Therapeutics Market, By Disease, 2017 - 2028 (USD Million)
  • Table 30 Saudi Arabia CNS Therapeutics Market, By Disease, 2017 - 2028 (USD Million)
  • Table 31 UAE CNS Therapeutics Market, By Disease, 2017 - 2028 (USD Million)

List of Figures

  • Fig. 1 CNS therapeutics market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Information procurement
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 QFD modeling for market share assessment
  • Fig. 8 Market formulation & validation
  • Fig. 9 CNS therapeutics market snapshot
  • Fig. 10 CNS therapeutics market driver impact
  • Fig. 11 CNS therapeutics market restraint impact
  • Fig. 12 Penetration and growth prospect mapping
  • Fig. 13 SWOT analysis, by factor (political & legal economic and technological)
  • Fig. 14 Porter's five forces analysis
  • Fig. 15 CNS therapeutics market: Disease outlook and key takeaways
  • Fig. 16 CNS therapeutics market: Disease movement analysis
  • Fig. 17 Disease segment dashboard
  • Fig. 18 Neurovascular diseases market estimates and forecast, 2017 - 2028 (USD Million)
  • Fig. 19 CNS trauma market estimates and forecast, 2017 - 2028 (USD Million)
  • Fig. 20 Mental health market estimates and forecast, 2017 - 2028 (USD Million)
  • Fig. 21 Anxiety disorders market estimates and forecast, 2017 - 2028 (USD Million)
  • Fig. 22 Epilepsy market estimates and forecast, 2017 - 2028 (USD Million)
  • Fig. 23 Mood disorders market estimates and forecast, 2017 - 2028 (USD Million)
  • Fig. 24 Psychotic disorders market estimates and forecast, 2017 - 2028 (USD Million)
  • Fig. 25 Other mental health market estimates and forecast, 2017 - 2028 (USD Million)
  • Fig. 26 Neurodegenerative diseases market estimates and forecast, 2017 - 2028 (USD Million)
  • Fig. 27 Alzheimer's disease market estimates and forecast, 2017 - 2028 (USD Million)
  • Fig. 28 Parkinson's disease market estimates and forecast, 2017 - 2028 (USD Million)
  • Fig. 29 Multiple sclerosis market estimates and forecast, 2017 - 2028 (USD Million)
  • Fig. 30 Huntington's disease market estimates and forecast, 2017 - 2028 (USD Million)
  • Fig. 31 Amyotrophic lateral sclerosis market estimates and forecast, 2017 - 2028 (USD Million)
  • Fig. 32 Other neurodegenerative diseases market estimates and forecast, 2017 - 2028 (USD Million)
  • Fig. 33 Infectious diseases market estimates and forecast, 2017 - 2028 (USD Million)
  • Fig. 34 CNS cancer market estimates and forecast, 2017 - 2028 (USD Million)
  • Fig. 35 Others market estimates and forecast, 2017 - 2028 (USD Million)
  • Fig. 36 CNS therapeutics market: Regional outlook and key takeaways
  • Fig. 37 Regional outlook, 2020 & 2028 (USD Million)
  • Fig. 38 Regional market dashboard
  • Fig. 39 North America
  • Fig. 40 North America market estimates and forecast, 2017 - 2028 (USD Million)
  • Fig. 41 U.S.
  • Fig. 42 U.S. market estimates and forecast, 2017 - 2028 (USD Million)
  • Fig. 43 Canada
  • Fig. 44 Canada market estimates and forecast, 2017 - 2028 (USD Million)
  • Fig. 45 Europe
  • Fig. 46 Europe market estimates and forecast, 2017 - 2028 (USD Million)
  • Fig. 47 Germany
  • Fig. 48 Germany market estimates and forecast, 2017 - 2028 (USD Million)
  • Fig. 49 U.K.
  • Fig. 50 U.K. market estimates and forecast, 2017 - 2028 (USD Million)
  • Fig. 51 Spain
  • Fig. 52 Spain market estimates and forecast, 2017 - 2028 (USD Million)
  • Fig. 53 France
  • Fig. 54 France market estimates and forecast, 2017 - 2028 (USD Million)
  • Fig. 55 Italy
  • Fig. 56 Italy market estimates and forecast, 2017 - 2028 (USD Million)
  • Fig. 57 Asia Pacific
  • Fig. 58 Asia Pacific market estimates and forecast, 2017 - 2028 (USD Million)
  • Fig. 59 Japan
  • Fig. 60 Japan market estimates and forecast, 2017 - 2028 (USD Million)
  • Fig. 61 China
  • Fig. 62 China market estimates and forecast, 2017 - 2028 (USD Million)
  • Fig. 63 India
  • Fig. 64 India market estimates and forecast, 2017 - 2028 (USD Million)
  • Fig. 65 South Korea
  • Fig. 66 South Korea market estimates and forecast, 2017 - 2028 (USD Million)
  • Fig. 67 Australia
  • Fig. 68 Australia market estimates and forecast, 2017 - 2028 (USD Million)
  • Fig. 69 Latin America
  • Fig. 70 Latin America market estimates and forecast, 2017 - 2028 (USD Million)
  • Fig. 71 Brazil
  • Fig. 72 Brazil market estimates and forecast, 2017 - 2028 (USD Million)
  • Fig. 73 Mexico
  • Fig. 74 Mexico market estimates and forecast, 2017 - 2028 (USD Million)
  • Fig. 75 Argentina
  • Fig. 76 Argentina market estimates and forecast, 2017 - 2028 (USD Million)
  • Fig. 77 Middle East & Africa
  • Fig. 78 Middle East & Africa market estimates and forecast, 2017 - 2028 (USD Million)
  • Fig. 79 South Africa
  • Fig. 80 South Africa market estimates and forecast, 2017 - 2028 (USD Million)
  • Fig. 81 UAE
  • Fig. 82 UAE market estimates and forecast, 2017 - 2028 (USD Million)
  • Fig. 83 Saudi Arabia
  • Fig. 84 Saudi Arabia market estimates and forecast, 2017 - 2028 (USD Million)